The Mean Global Prevalence of CKD, Across all five Stages of the Disease, is Estimated to be 13.4%
Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over 90% of the patients suffering from reduced kidney function are unaware of their medical condition. In the US, 15% of adults are reported to be suffering from mild or severe forms of CKD. In fact, the mean global prevalence of CKD, across all five stages of the disease, is estimated to be 13.4%. Limited availability of epidemiological data, lack of awareness, late diagnosis and inappropriate/incorrect treatment are some of the factors responsible for elevating disease incidence. It is also worth noting that developed nations spend over 2-3% of their annual healthcare budget on the treatment of end-stage renal disease (ESRD); however, the economic burden associated with milder forms of CKD is almost double the total costs incurred in the treatment of ESRD. Further, in the US, the disease has been estimated to incur combined direct and indirect costs ranging between USD 1,183 - USD 35,292 per patient, per month.
Existing therapeutic options have already been proven to be inadequate in containing the progression of the disease and its symptoms in the long term. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease-modifying pharmacological interventions and therapies that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital funding in order to expedite the development of potential therapeutic options for better disease management.
The “Chronic Kidney Disease Market: Pipeline Review, Developer Landscape, and Competitive Insights” report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of chronic kidney disease.
The report includes:
- A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease-modifying agent or drugs offering symptomatic relief), mechanism of action, and route of administration of the drugs being developed for the treatment of chronic kidney disease.
- An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a heptagon representation, highlighting the distribution of the marketed and development stage molecules based on the target clinical condition, [B] a 2X2 grid analysis, representing the distribution of drug candidates across various disease indications, dosing frequencies and stages of development, and [C] a diagrammatic representation of the regional landscape of industry players involved in the development of drugs in this domain, distributed based on the location of their headquarters.
- An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population (for the trial in the highest phase of development), route of administration, treatment type (disease-modifying agent and drugs offering symptomatic relief) and dosing frequency (for quantifying clinical attractiveness), and target patient population, expected launch date and size of developer company (for quantifying commercial attractiveness).
- An analysis highlighting the key unmet needs across chronic kidney disease, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, patient blogs and the views of key opinion leaders expressed on online platforms.
- An insightful competitive analysis, highlighting the key players in the domain on the basis of the strength of their respective development portfolios, taking into account company size and the stage of development of lead molecules in their respective pipelines.
- A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
- An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and commercialization agreements, manufacturing agreements, and others
- An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.
The research, analysis, and insights presented in this report are backed by a deep understanding of insights gathered from secondary sources. The opinions and insights presented in this study were influenced by inputs of several key players in this domain. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD unless otherwise specified.
Example Highlights
- The analysis of content presented on informal (100 patient blogs and over 3,000 social media posts) and formal (180 scientific articles) literary sources, and the opinions expressed by industry experts confirm the existence of a significant unmet need within the chronic kidney disease market. Some of the unaddressed concerns suggested across multiple portals include improved therapeutic strategies, better management of comorbidities, lack of awareness related to the conditions leading to chronic kidney disease, high economic burden, unavailability of dialysis centers and poor quality of life.
- Presently, over 160 product candidates are being evaluated across various stages of development for the management/treatment of chronic kidney disease. Of these, 24% are in the preclinical or discovery phase. Amongst the drugs that are under clinical development, 33 are in phase III / pre-registration, 47 in phase II, and 22 in phase I and phase I/II trials. Interestingly, since 2012, 22 product candidates have been commercialized; examples include JYNARQUE® (2018), Parsabiv™ (2017), RAYALDEE® (2016) and VELTASSA® (2015).
- Majority of novel drug candidates (close to 70%) are disease-modifying agents, while nearly 30% designed to provide symptomatic relief only. It is worth highlighting that 75% of pipeline candidates are small molecules, and the rest are biologics. Further, most are being developed as monotherapies (close to 75%), whereas nearly 25% are currently being investigated as combination therapies.
- The market landscape is characterized by the presence of large (31), mid-sized (33) and small-sized companies (47). Examples of prominent large companies engaged in this domain include (in alphabetical order, no selection criteria) Amgen, Asahi Kasei Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer and Sanofi. The growing unmet need within this domain has spurred the establishment of many start-ups / small-sized companies in recent years; examples include (in alphabetical order, no selection criteria) Algomedix, Angion Biomedica, Anthera Pharmaceuticals, Apellis Pharmaceuticals, Complexa, Ember Therapeutics, Genkyotex, Goldfinch Bio, inRegen, Kezar Life Sciences, Lanthio Pharma, Orbis Biosciences, Redx pharma, Sanifit, and Serodus.
- Stakeholders in the industry have forged several strategic partnerships in the recent past; we observed that 28% of the agreements that were signed between 2015 and 2018 were related to research and development. These were followed by development and commercialization agreements (23%), licensing agreements (22%), commercialization agreements (15%), acquisitions (5%), mergers (5%), and manufacturing agreements (2%). Examples of recently inked deals include collaborations between Novo Nordisk and Evotec (August 2018), Resverlogix and Medison Pharma (January 2018), and AstraZeneca and Ionis Pharmaceuticals (February 2018).
- Drug development initiatives by start-ups have received financial support in terms of venture funding and research grants. In fact, more than USD 4.1 billion, across 118 instances of grants, venture capital rounds, and public offerings, has been invested in these companies since 2010. Across all the funding rounds, the most active investors include (in terms of participation in funding rounds) Omega Funds, Flagship Pioneering, Polaris Partners, venBio Select, Oxford Finance, OrbiMed Advisors, Morningside Group, Limulus Venture Partners, Cormorant Asset Management, AJU IB Investment, and Sibling Capital.
- Several prominent scientists (over 100) have made significant contributions in advancing the clinical development efforts, and therefore, have emerged as key opinion leaders in this field. Examples of prominent universities and hospitals that have been engaged in conducting breakthrough research in this domain include (in alphabetical order, no selection criteria) Icahn School of Medicine, UC San Diego School of Medicine, University of Michigan, University of Oxford and Vanderbilt University Medical Center.
Table of Contents
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. An Overview of Chronic Kidney Diseases
3.2.1. Medical Conditions Associated with Chronic Kidney Diseases
3.2.1.1. Alport Syndrome
3.2.1.2. Diabetic Nephropathy
3.2.1.3. Focal Segmental Glomerulosclerosis
3.2.1.4. Glomerulonephritis
3.2.1.5. Nephrotic Syndrome
3.2.1.6. Polycystic Kidney Disease
3.2.1.7. Hypertensive Kidney Disease
3.2.1.8. Pyelonephritis
3.2.2. Stages of Chronic Kidney Disease
3.2.3. Symptoms
3.2.4. Diagnosis
3.2.5. Treatment Options
3.2.5.1. Therapeutics
3.2.5.2. Other Modalities
3.2.7. Kidney Transplant and Implications
4. Pipeline Review: Marketed And Development Drugs
4.1. Chapter Overview
4.2. Drugs for Chronic Kidney Disease: Marketed and Development Pipeline
4.3. Chronic Kidney Disease: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Route of Administration
4.3.4. Analysis by Target Therapeutic Indication(s)
4.3.5. Analysis by Size of Developer
4.3.6. Analysis by Size and Location of the Players
4.3.7. Analysis of Leading Developers
4.3.8. Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
4.3.9. Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
4.3.10. Geographical Landscape
5. Product Clinical Commercial Attractiveness
5.1. Chapter Overview
5.2. Methodology
5.2.1. Assumptions and Key Parameters
5.3. Affiliated Insights
6. Chronic Kidney Disease: Unmet Needs Analysis
6.1. Chapter Overview
6.2. Unmet Needs Analysis in Chronic Kidney Disease
6.2.1. Unmet Needs Expressed in Patient Blogs
6.2.1.1. Methodology
6.2.1.2. Key Insights
6.2.2. Unmet Needs Reported in Published Literature
6.2.2.1. Methodology
6.2.2.2. Key Insights
6.2.3. Unmet Needs Expressed on Social Media Platforms
6.2.3.1. Methodology
6.2.3.2. Key Insights
6.2.4. Unmet Needs Highlighted by Experts
6.2.4.1. Titte Srinivas, Intermountain Medical Centre
6.2.4.2. Brian Clement, Hippocrates Health Institute
6.2.4.3. Frank Brennan, Palliative Care Physician
6.2.4.4. Sarah Brook, Renal Dietitian, Salford Royal NHS Foundation Trust
6.2.4.5. Joseph Selvanayagam, Medical Researcher, Flinders University
6.2.4.6. Vanessa Rojas-Bautista, UC Irvine Health
6.2.5. Concluding Remarks: Key Unmet Needs in Chronic Kidney Disease
7. Company Competitiveness Analysis
7.1. Chapter Overview
7.2. Methodology
7.2.1. Assumptions and Key Parameters
7.3. Company Competitiveness Analysis: Key Insights
7.3.1. Key Players: North America
7.3.2. Key Players: Europe
7.3.3. Key Players: Asia Pacific
8. KOL Analysis
8.1. Chapter Overview
8.2. Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.4. Prominent Key Opinion Leaders
8.5. Most Active Key Opinion Leaders
9. Partnerships and Collaborations
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Therapeutics for Chronic Kidney Disease: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements
10. Funding And Investment Analysis
10.1. Chapter Overview
10.2. Types of Funding
10.3. Novel Therapeutics for Chronic Kidney Disease: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Most Active Players
10.3.5. Most Active Investors
10.4. Concluding Remarks
11. Appendix 1: Tabulated Data
12. Appendix 2: List of Companies and Organizations
List of Tables
Table 3.1 Indicative Values of Focal Segmental Glomerulosclerosis
Table 3.2 Stages of Chronic Kidney Disease
Table 4.1 Chronic Kidney Disease: Marketed and Development Pipeline
Table 5.1 Clinical Trial Analysis: Final Output
Table 8.1 KOL Analysis: List of Principal Investigators
Table 8.2 KOL Analysis: List of Universities and Hospitals
Table 8.3 KOL Analysis: Scoring System
Table 8.4 KOL Profile: Bernard Canaud, Clinical Trials
Table 8.5 KOL Profile: Bernard Canaud, Published Literature
Table 8.6 KOL Profile: Christopher Wilcox, Clinical Trials
Table 8.7 KOL Profile: Christopher Wilcox, Published Literature
Table 8.8 KOL Profile: Csaba P Kovesdy, Clinical Trials
Table 8.9 KOL Profile: Csaba P Kovesdy, Published Literature
Table 8.10 KOL Profile: Ian H de Boer, Clinical Trials
Table 8.11 KOL Profile: Ian H de Boer, Published Literature
Table 8.12 KOL Profile: Stanley Jordan, Clinical Trials
Table 8.13 KOL Profile: Stanley Jordan, Published Literature
Table 9.1 Chronic Kidney Disease: Partnerships and Collaborations, 2015-2018
Table 10.1 Chronic Kidney Disease: Funding and Investments, 2010-2018
Table 10.2 Funding and Investment Analysis: Summary of Investments
Table 11.1 Chronic Kidney Diseases: Epidemiology
Table 11.2 Pipeline Analysis: Distribution by Phase of Development
Table 11.3 Pipeline Analysis: Distribution by Type of Molecule
Table 11.4 Pipeline Analysis: Distribution by Route of Administration
Table 11.5 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Table 11.6 Pipeline Analysis: Distribution by Size of Developer
Table 11.7 Pipeline Analysis: Leading Players
Table 11.8 Pipeline Analysis: Distribution by Size and Location of the Players
Table 11.9 Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
Table 11.10 Geographical Landscape Analysis: Distribution by Developers and their Headquarters
Table 11.11 Unmet Needs in Chronic Kidney Disease: Needs Highlighted in Published Literature
Table 11.12 Unmet Needs in Chronic Kidney Disease: Social Media Platforms, Sentiment Analysis
Table 11.13 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2018
Table 11.14 Partnerships and Collaborations: Distribution by Type of Partnership
Table 11.15 Partnerships and Collaborations: Most Active Players
Table 11.16 Partnerships and Collaborations: Regional Distribution
Table 11.17 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 11.18 Funding and Investment Analysis: Cumulative Number of Instances, 2010-2018
Table 11.19 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2018 (USD Million)
Table 11.20 Funding and Investment Analysis: Distribution by Type of Funding, 2010-2018
Table 11.21 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Table 11.22 Chronic Kidney Disease: Summary of Investments, January 2010-July 2018 (USD Million)
Table 11.23 Funding and Investment Analysis: Most Active Players
Table 11.24 Funding and Investment Analysis: Most Active Investors
Table 11.25 Funding and Investment Summary
List of Figures
Figure 3.1 Chronic Kidney Diseases: Epidemiology
Figure 3.2 Diabetic Nephropathy: Disease Progression
Figure 3.3 Chronic Kidney Diseases: Symptoms
Figure 3.4 Chronic Kidney Diseases: Diagnostic Techniques
Figure 3.5 Chronic Kidney Diseases: Treatment Options
Figure 3.6 ACE Inhibitors: Mechanism of Action
Figure 3.7 Statins: Mechanism of Action
Figure 3.8 Loop Diuretics: Mechanism of Action
Figure 3.9 Thiazide Diuretics: Mechanism of Action
Figure 3.10 Kidney Transplant: Associated Challenges
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Molecule
Figure 4.3 Pipeline Analysis: Distribution by Route of Administration
Figure 4.4 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Figure 4.5 Pipeline Analysis: Distribution by Size of Developer
Figure 4.6 Pipeline Analysis: Leading Developers
Figure 4.7 Pipeline Analysis: Distribution by Size and Location of the Players
Figure 4.8 Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
Figure 4.9 Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
Figure 4.10 Geographical Landscape
Figure 5.1 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Anemia
Figure 5.2 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Diabetic Nephropathy and Nephrotic Syndrome
Figure 5.3 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Focal Segmental Glomerulosclerosis
Figure 5.4 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for IgA Nephropathy
Figure 5.5 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Lupus Nephritis and Pyelonephritis
Figure 5.6 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for CKD (Indication Unspecified)
Figure 6.1 Unmet Needs Analysis: Overview of the Methodology
Figure 6.2 Unmet Needs in Chronic Kidney Disease: Word Cloud of Patient Blogs
Figure 6.3 Unmet Needs in Chronic Kidney Disease: Needs Highlighted in Published Literature
Figure 6.4 Unmet Needs in Chronic Kidney Disease: Social Media Sentiment Analysis
Figure 6.5 Unmet Needs in Chronic Kidney Disease: Social Media Word Cloud on Total Tweets
Figure 6.6 Unmet Needs in Chronic Kidney Disease: Social Media Word Cloud on Specific Indications
Figure 6.7 Chronic Kidney Disease: Key Unmet Needs
Figure 7.1 Company Competitiveness Analysis: Key Players in North America
Figure 7.2 Company Competitiveness Analysis: Key Players in Europe
Figure 7.3 Company Competitiveness Analysis: Key Players in Asia Pacific
Figure 8.1 KOL Analysis: Geographical Location of Principal Investigators
Figure 8.2 KOL Analysis: Dot-Plot of Principal Investigators
Figure 8.3 KOL Analysis: Most Active Key Opinion Leaders
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2018
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Most Active Players
Figure 9.4 Partnerships and Collaborations: Regional Distribution
Figure 9.5 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Funding and Investment Analysis: Cumulative Number of Instances, 2010-2018
Figure 10.2 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2018 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution by Type of Funding, 2010-2018
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Figure 10.5 Chronic Kidney Disease: Summary of Investments, 2010-2018 (USD Million)
Figure 10.6 Funding and Investment Analysis: Most Active Players
Figure 10.7 Funding and Investment Analysis: Most Active Investors
Figure 10.8 Funding and Investment Summary
Executive Summary
Research Methodology
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews/surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
Chapter Outlines:
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view of the likely evolution of the chronic kidney disease market in the long term.
Chapter 3 provides an introduction to chronic kidney disease and its associated comorbidities. It features a detailed discussion on the development, symptoms, and stages of the condition, factors influencing disease progression and the various treatment regimens that are available in the market. It also includes a discussion on the epidemiology of the disease and the associated economic burden across various regions.
Chapter 4 includes information on over 160 molecules that are currently approved / under development for therapeutic use. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (clinical, preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease-modifying agent or drugs offering symptomatic relief), mechanism of action, and route of administration of the drug candidates. In addition, it presents certain key insights derived from the study, which include a heptagon representation highlighting the distribution of the marketed and pipeline molecules based on different clinical indications. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of drug candidates across various indications, dosing frequencies and stages of development. Additionally, the chapter features a regional landscape of developers engaged in this domain, distributed on the basis of the location of their headquarters.
Chapter 5 features an analysis of the clinical and commercial attractiveness of the drugs designed for the treatment of CKD and its associated comorbidities. The drugs are plotted on a 2X2 matrix, with clinical attractiveness (abscissa) and commercial attractiveness (ordinate) as the two axes. The clinical attractiveness of a drug is determined by the sample size of its trial (highest phase), route of administration, treatment type (disease-modifying agent and drugs offering symptomatic relief) and dosage frequency. The commercial attractiveness of a drug is determined by the target population size, expected launch date and the company size.
Chapter 6 highlights the key unmet needs associated with the management and treatment of chronic kidney disease. The chapter provides a detailed analysis of unmet needs that were identified from views expressed by patients/experts across different platforms, such as social media posts, recent publications and patient blogs, and the inputs of key opinion leaders at conferences/symposiums. The chapter presents an insightful sentiment analysis and word cloud analysis, summarizing the opinions expressed across public portals.
Chapter 7 presents an analysis of the competitive landscape of companies involved in the development of novel therapeutics for the treatment of chronic kidney disease. It is based on the number of molecules in the pipelines of different players (taking into consideration the current status of development) and company size (in terms of the number of employees). In this analysis, companies across different regions (North America, Europe, and Asia-Pacific) were plotted on 2X2 matrices, having company pipeline strengths the ordinate and company size as the abscissa.
Chapter 8 provides an analysis of KOLs in the field of chronic kidney disease. It features a comprehensive list of principal investigators of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists/researchers who are engaged in clinical research in this domain. It also features a comparative analysis, highlighting those KOLs who have relatively more experience in this domain.
Chapter 9 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including product development and commercialization, R&D agreements, technology/product licensing agreements, other licensing agreements, mergers/acquisitions and clinical trial collaborations) and the most common forms of deals/agreements that have been established between 2015 to 2018.
Chapter 10 presents details on various investments received by companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, in the period between 2010 and July 2018, highlighting the growing interest of the venture capital community and other strategic investors in this market.
Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 12 is an appendix, which contains the list of companies and organizations mentioned in the report.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aarhus University
- Achillion Pharmaceuticals
- Advantech Capital
- AJU IB Investment
- Akebia Therapeutics
- Albany College of Pharmacy and Health Sciences
- Alexandria Venture Investments
- Alexion Pharmaceuticals
- Algomedix
- Allegheny Financial Group
- Amgen
- Amyndas Pharmaceuticals
- Angion Biomedica
- Anthera Pharmaceuticals
- apceth Biopharma
- Apellis Pharmaceuticals
- Apollo Hospitals
- AptaBio Therapeutics
- Ardelyx
- Armetheon
- Asahi Kasei Pharma
- Astellas Pharma
- AstraZeneca
- Aurinia Pharmaceuticals
- Avexxin
- Barclays Bank
- Bay City Capital
- Bayer
- Baylor College of Medicine
- Beijing Anzhen Hospital
- Bichat-Claude Bernard Hospital
- Bill & Melinda Gates Foundation
- BIOCAD
- BioVirtus
- BLR Bio
- Boehringer Ingelheim
- Boryung Pharmaceutical
- Bristol-Myers Squibb
- California Institute of Renal Research
- Calliditas Therapeutics
- Cara Therapeutics
- CARB-X
- Cash Capital
- Cedars-Sinai Medical Center
- Celgene
- Cellmid
- Centre Hospitalier Universitaire
- ChemoCentryx
- Children's Mercy Hospital
- China Medical University Hospital
- Chugai Pharmaceutical
- Clough Capital
- Complexa
- Concert Pharmaceuticals
- Cormorant Asset Management
- Cowen Healthcare Investments
- Cowin Capital Group
- Creighton University
- CTI Life Sciences Fund
- CuraGen
- Cycad Group
- Daiichi Sankyo
- DaVita Clinical Research
- DiaMedica Therapeutics
- Dimerix
- Dong-A ST
- Dongguk University
- Duke University
- Dynavax Technologies
- Eastern Capital
- EcoR1 Capital
- Edmond de Rothschild Investment Partners
- Efung Capital
- Ege University
- ElexoPharm
- Eli Lilly and Company
- Elite Capital
- Ember Therapeutics
- Epidarex Capital
- Epigen Biosciences
- Espero BioPharma
- Evanston Northwestern Hospital
- Evotec
- F-Prime Capital Partners
- Flagship Pioneering
- Foresee Pharmaceuticals
- Fosun Pharma
- Fresenius Medical Care
- Fudan University
- Gabriele d’Annunzio’ University
- Galectin Therapeutics
- Galencia
- Gazi University
- Genentech
- Genexine
- Genkyotex
- George Washington University
- Georgetown University
- Gilead Sciences
- GlaxoSmithKline
- Glycadia Pharmaceuticals
- GNI Group
- Goldfinch Bio
- Goldman Sachs
- Gujarat Kidney Foundation
- H.C. Wainwright
- Hadassah Medical Center
- Hamad Medical
- Hanmi Pharmaceutical
- Hansa Medical
- HBM Healthcare Investments
- Heidelberg University
- Hennepin Healthcare
- Hercules Capital
- Hermed Capital
- Hoffmann-La Roche
- Hospital Aleman
- Human Genome Sciences
- Hydra Biosciences
- Icahn School of Medicine at Mount Sinai
- Idera Pharmaceuticals
- Indiana University
- Innovation Network Corporation of Japan
- Inositec
- inRegen
- Inselspital
- Ionis Pharmaceuticals
- Iran University of Medical Sciences
- Ironwood Pharmaceuticals
- Italian Hospital
- JAFCO
- Janssen Pharmaceuticals
- Japan Tobacco International
- Jiangsu Maslech Medical Technology
- Johns Hopkins University
- JPMorgan Chase
- Kadmon
- KAI Pharmaceuticals
- KBP Biosciences
- Keryx Biopharmaceuticals
- Kezar Life Sciences
- King's College London
- KISSEI Pharmaceutical
- Klotho Therapeutics
- Knight Therapeutics
- Konkuk University
- Korea Investment Partners
- Kyowa Hakko Kirin
- Kyung Hee University
- L&F Research
- La Jolla Pharmaceutical
- Lanthio Pharma
- Lawson Health Research Institute
- LCR Clinical Research
- Lexicon Pharmaceuticals
- LG Life Sciences
- Limulus Venture Partners
- London Health Sciences Centre
- Longitude Capital
- Lonza
- Mallinckrodt Pharmaceuticals
- Mannkind Corporation
- Mariel Therapeutics
- Maruishi Pharmaceutical
- Massachusetts General Hospital
- Mayo Clinic
- McMaster University
- Medical University of Graz
- Medicxi Ventures
- MedImmune
- Medipal Holdings
- Medison Pharma
- Megapharm
- Merck Serono
- Merck Sharp & Dohme
- Michigan State University
- Mission Therapeutics
- Mitsubishi Tanabe Pharma
- Morningside Ventures
- MRL Ventures Fund
- National Taiwan University Hospital
- Necker-Enfants Malades Hospital
- Nephrotic Syndrome Study Network
- New Enterprise Associates
- NorthShore University HealthSystem
- Novadiol
- Novartis Institutes for Biomedical Research
- Novartis Pharmaceuticals
- Novo Nordisk
- NOXXON Pharma
- Omega Funds
- OPKO Health
- Orange County Research Center
- Oraxion Therapeutics
- OrbiMed
- Orbis Biosciences
- Oregon Health & Science University
- Otsuka Pharmaceuticals
- Ottawa Hospital Research Institute
- Oxford Finance
- Palladio Biosciences
- Pappas Ventures
- Paranta Biosciences
- Pfizer
- Pfizer Venture Investments
- Pharmacosmos
- Ping An Ventures
- PKD Foundation
- Polaris Partners
- Prometic Life Sciences
- Proteomics International
- Proteon Therapeutics
- Qiming Venture Partners
- Queen Mary’s Hospital
- Reata Pharmaceuticals
- Redx Pharma
- Regulus Therapeutics
- Relypsa
- Resverlogix
- Retrophin
- Rigel Pharmaceuticals
- Roche
- Rockwell Medical
- Sahlgrenska University Hospital
- Samsung Medical Center
- Sandoz
- Sangel Capital
- Sanifit
- Sanofi
- SCOHIA PHARMA
- SDIC Venture Capital
- Sectoral Asset Management
- Seoul National University
- Seoul St. Mary's Hospital
- Serodus
- Serum Institute of India
- Severance Hospital
- Shenyang Sunshine Pharmaceutical
- Shenzhen Hepalink Pharmaceutical
- Shield Therapeutics
- Sibling Capital Ventures
- Silicon Valley Bank
- Silver Creek Pharmaceuticals
- SK Group
- Sofinnova Ventures
- St. George's University
- Stanford University
- Sumitomo Dainippon Pharma
- Taipei Medical University
- Taisho Pharmaceutical
- Takeda Pharmaceuticals
- Teijin Pharma
- Tel Aviv Sourasky Medical Center
- The George Institute for Global Health
- The Medical University of South Carolina
- The Rogosin Institute
- The University of Alabama
- The University of British Columbia
- Theravance Biopharma
- Third Rock Ventures
- Thynk Capital
- Tokai University
- Toronto General Hospital
- TR-Pharm
- Trevi Therapeutics
- Tricida
- Trisaq
- Tufts Medical Center
- UC San Diego School of Medicine
- UnicoCell Biomed
- Unicyte
- University Hospital Bonn
- University Hospital Center De Montpellier
- University Hospitals Birmingham
- University of Calgary
- University of California
- University of Cincinnati
- University of Frankfurt
- University of Giessen
- University of Guadalajara
- University of Illinois
- University of Kentucky
- University of Leeds
- University of Louisville
- University of Manitoba
- University of Maryland
- University of Michigan
- University of Minnesota
- University of Missouri
- University of Montreal
- University of North Carolina
- University of Oklahoma
- University of Oxford
- University of Pennsylvania
- University of Ulsan
- University of Utah
- University of Wisconsin
- University of Zurich
- Uppsala University Hospital
- Vanderbilt University Medical Center
- Variant Pharmaceuticals
- venBio Global Strategic Fund
- venBio Select
- Venrock Healthcare Capital Partners
- Verily Life Sciences
- Vertex Venture Holdings
- Vidasym
- Vifor Fresenius Medical Care Renal Pharma
- Vifor Pharma
- Visterra
- Vivo Capital
- Washington University School of Medicine
- Watson Laboratories
- Wellington Management
- XORTX Therapeutics
- Yuhan Corporation
- Zeria Pharmaceutical
- ZS Pharma
Methodology
LOADING...
